Human Vaccine

Human Vaccine - most related articles:

- Novartis inaugurates influenza vaccine manufacturing facility - 4.4
- Human vaccine against bird flu soon - 4.3
- Many parents, high priority adults didn't get H1N1 vaccine - 4.3
- Universal Influenza vaccine holds promise - 4.3
- Swine flu vaccine candidate prepared by UK - 4.3
- H1N1 flu vaccination begins for school children in US - 4.2
- Ixiaro to prevent Japanese Encephalitis approved in Europe - 4.2
- Universal influenza vaccine possible in future - 4.1
- 21% children not fully protected against vaccine-preventable diseases - 4.1
- Gardasil vaccine to prevent cervical cancer in India - 4.1

Human Vaccine articles

Antibodies can stop most HIV strains from infecting human cells
Scientists have discovered two potent human antibodies that can stop more than 90 percent of known global HIV strains from infecting human cells in the laboratory, and have demonstrated how one of these disease-fighting proteins accomplishes this feat.

$884 million to purchase H1N1 vaccine, US
U.S. Department of Health & Human Services' Secretary Kathleen Sebelius announced that the health department will commit $884 million to purchase additional supplies of two key ingredients for potential H1N1 vaccine to further prepare the nation for a potential resurgence of the 2009 H1N1 virus.

AIDS virus damages gut antibody-producing immune cells
A new research from the NIAID-funded Center for HIV/AIDS Vaccine Immunology suggests that HIV-1 is anything but – moving at breathtaking speed in destroying and dysregulating the body's gut-based B-cell antibody-producing system.

Benefit to women not enough to sway men to get HPV vaccine
Informing men that a new vaccine to prevent human papillomavirus (HPV) would also help protect their female partners against developing cervical cancer from the sexually transmitted infection did not increase their interest in getting the vaccine, according to a new Florida State University study.

Gardasil is eligible for UN immunization programs
GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], Merck's cervical cancer vaccine, has been awarded World Health Organization (WHO) pre-qualification. GARDASIL is the first cervical cancer vaccine to receive WHO pre-qualification.

Gardasil efficacious against HPV 16 infection
In a study of an extended follow up of 290 women naïve to HPV type 16, the HPV 16 component of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] was efficacious against HPV 16 infection for an average of 8.5 years after administration.

Human vaccine against bird flu soon
A vaccine to protect humans from a bird flu pandemic is within reach after a new discovery by researchers at the University of Melbourne, Australia.

Meningitis bacteria mimic as human cells to evade immune system
The way in which bacteria that cause bacterial meningitis mimic human cells to evade the body's innate immune system has been revealed by researchers at the University of Oxford and Imperial College London.

Gardasil approval delayed for use in women ages 27 - 45
Merck & Co., Inc. announced that the U.S. Food and Drug Administration has issued a second complete response letter regarding the supplemental biologics license application (sBLA) for the use of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] in women ages 27 though 45.

HPV vaccine's hypersensitivity reactions are rare
Hypersensitivity reactions to the quadrivalent HPV vaccine (4vHPV, Gardasil) are uncommon and most schoolgirls can tolerate subsequent doses, finds the first evaluation of the quadrivalent HPV vaccine published on bmj.com.

Gardasil HPV vaccine prevented genital lesions in men
GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], the cervical cancer vaccine from Merck & Co., Inc., prevented 90 percent of external genital lesions caused by human papillomavirus (HPV) types 6, 11, 16 and 18 in a pivotal Phase III study in men aged 16 to 26.

US to bulk purchase BioThrax anthrax vaccine from Emergent BioSolutions
Emergent BioSolutions Inc. (NYSE:EBS) announced that it has signed a new, multi-year, firm fixed price contract with the U.S. Department of Health and Human Services (HHS) to supply an additional 14.5 million doses of BioThrax(R) (Anthrax Vaccine Adsorbed), its FDA licensed anthrax vaccine, for inclusion in the Strategic National Stockpile (SNS).

Mothers less likely to vaccinate daughters against HPV
U.S. mothers report they are less likely to vaccinate daughters under age 13 against human papillomavirus virus (HPV), even though the vaccine is recommended for girls at age 11 and 12, it's incumbent upon the healthcare community to work to improve mom's acceptance of the vaccination for younger daughters, say researchers at Cincinnati Children's Hospital Medical Center who conducted the study.

13 Human Vaccine articles listed above.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
1.76